Research and preclinical development
Currently, the majority of our research activities are in immuno-oncology and focused on identifying antibodies against novel targets to mobilize the immune system to fight tumors.
The goal of our research programs is to identify best or first in class drug candidates that can provide therapeutic options for patients whose tumors fail to respond or become resistant to first generation immuno-oncology drugs.
Competitive timelines to IND
Symphogen has proven its ability to deliver unique antibodies on aggressive timelines as exemplified with our filing of three INDs in six months – Sym021, Sym022 and Sym023. Such an exceptional achievement is made possible by the unique way we run projects. Developability assessment is an integrated part of the lead selection process, which means that potential critical features of the lead candidates are taken into consideration very early in the development path.
Once the lead is selected, pre-clinical development is based on a solid, standardized platform where only minor adaption to the lead is typically needed, a balanced out-sourcing strategy and a cross-functionally aligned development plan, where critical path activities are staggered to minimize the overall timeline.